Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2015

01-05-2015 | Research Article

Comparing CTVs for permanent prostate brachytherapy

Authors: C. A. Oton, L. Blanco, L. F. Oton, S. Moral

Published in: Clinical and Translational Oncology | Issue 5/2015

Login to get access

Abstract

Background and purpose

To delineate the clinical target volume (CTV) in low dose rate (LDR) brachytherapy for prostate cancer, American Brachytherapy Society (ABS) recommends a CTV = prostate. ESTRO advocates a CTV = prostate + 3 mm excluding rectum and many authors use and recommend other different CTVs. This study aims to: (1) evaluate the appropriateness of these recommendations and (2) test the applicability of seed distributions on the different CTVs and contrast the dosimetric differences.

Materials and methods

Ninety-eight patients treated with 125I seeds (dose 145 Gy; CTV = prostate) were studied. We established for every patient: (1) risk of extraprostatic extension (EPE), (2) adequacy of original plan to an extended CTV with 3 mm-margin (3) a new planning and seed distribution for this CTV and (4) comparison of dosimetry of both plans.

Results

Mean risk of EPE was 28.46 %. Original plan, when applied to the extended CTV, resulted in unsatisfactory dosimetry. A plan was generated for the 98 extended CTVs meeting all dosimetric specifications.

Conclusions

The risk of EPE is high enough to consider a 3 mm-margin around prostate necessary for all cases. A CTV = prostate + 3 mm except rectum as ESTRO recommends is feasible and would adjust planning to the most probable extension of the tumor.
Literature
1.
Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of the prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44(4):789–99.CrossRefPubMed
2.
Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys. 1995;22(2):209–34.CrossRefPubMed
3.
Rosenthal S, Bittner N, Beyer D, Demanes D, Goldsmith B, Horwitz E, et al. American Society for Radiation Oncology and American College of Radiology practice guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2011;79(2):335–41.CrossRefPubMed
4.
Davis B, Horwitz E, Lee W, Crook J, Stock R, Merrick G, et al. American Brachytherapy Society consensus guidelines for transrectal brachytherapy. Brachytherapy. 2012;11(1):6–19.CrossRefPubMed
5.
Hoskin PJ, Venselaar J, Group GEB, Group GEP. Prostate brachytherapy in Europe: growth, practice and guidelines. Radiother Oncol. 2007;83(1):1–2.CrossRef
6.
Salembier C, Lavagnini P, Nickers P, Mangili P, Rijnders A, Polo A, et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol. 2007;83(1):3–10.CrossRefPubMed
7.
Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA. 1997;277(18):1445–51.CrossRefPubMed
8.
Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58(6):843–8.CrossRefPubMed
9.
Partin AW, Yoo J, Carter HB, Pearson JD, Cha DV, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150(1):110–4.PubMed
10.
Davis B, Pisansky T, Wilson T, Rothenberg H, Pacelli A, Hillman D, et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer. 1999;85(12):2630–7.CrossRefPubMed
11.
Schwartz DJ, Sengupta S, Hillman DW, Sargent DJ, Cheville JC, Wilson TM, et al. Prediction of radial distance of extraprostatic extension from pretherapy factors. Int J Radiat Oncol Biol Phys. 2007;69(2):411–8.CrossRefPubMed
12.
Chao K, Goldstein N, Yan D, Vargas C, Ghilezan M, Korman H, et al. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension? Int J Radiat Oncol Biol Phys. 2006;65(4):999–1007.CrossRefPubMed
13.
Davis B, Pisansky T, Wilson T, Rothenberg H, Pacelli A, Hillman D, et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer. 1999;85(12):2630–7.CrossRefPubMed
14.
Teh B, Bastasch M, Mai W, Butler E, Wheeler T. Predictors of extracapsular extension and its radial distance in prostate cancer: implications for prostate IMRT, brachytherapy, and surgery. Cancer J. 2003;9(6):454–60.CrossRefPubMed
15.
Villers A, McNeal J, Freiha F, Boccon-Gibod L, Stamey T. Invasion of Denonvilliers’ fascia in radical prostatectomy specimens. J Urol. 1993;149(4):793–8.PubMed
16.
Edge S, Byrd D, Compton C. AJCC Cancer staging manual, 7th ed. 2010; p. 457–468.
17.
Hsiao W, Moses K, Goodman M, Jani A, Rossi P, Master V. Stage IV prostate cancer: survival differences in clinical T4, nodal and metastatic disease. J Urol. 2010;184(2):512–8.CrossRefPubMed
18.
Pierorazio P, Epstein J, Humphreys E, Han M, Walsh P, Partin A. The significance of a positive bladder neck margin after radical prostatectomy: the American Joint Committee on Cancer Pathological Stage T4 designation is not warranted. J Urol. 2010;183(1):151–7.CrossRefPubMed
19.
Ploussard G, Rotondo S, Salomon L. The prognostic significance of bladder neck invasion in prostate cancer: is microscopic involvement truly a T4 disease? BJU Int. 2010;105(6):776–91.CrossRefPubMed
20.
Stone N, Stock R, Cesaretti J, Unger P. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys. 2010;76(2):355–60.CrossRefPubMed
21.
Forsythe K, Burri R, Stone N, Stock R. Predictors of metastatic disease after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2012;83(2):645–52.CrossRefPubMed
22.
Burri R, Stone N, Unger P, Stock R. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;77(5):1338–44.CrossRefPubMed
23.
Burri R, Ho A, Forsythe K, Cesaretti J, Stone N, Stock R. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;77(5):1315–21.CrossRefPubMed
24.
Forsythe K, Blacksburg S, Stone N, Stock R. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 2012;83(2):630–5.CrossRefPubMed
25.
Goldner G, Pötter R, Battermann J, Kirisits C, Schmid M, Sljivic S, et al. Comparison between external beam radiotherapy (70 Gy/74 Gy) and permanent interstitial brachytherapy in 890 intermediate risk prostate cancer patients. Radiother Oncol. 2012;103(2):223–7.CrossRefPubMed
26.
Stock R, Buckstein M, Liu J, Stone N. The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes. BJU Int. 2013;112(2):44–50.CrossRef
27.
Roeloffze E, Lips I, van Gellekom M, van Roermund J, Frank S, Battermann J, et al. Health-related quality of life up to six years after (125)I brachytherapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76(4):1054–60.CrossRef
28.
Keyes M, Crook J, Morris W, Morton G, Pickles T, Usmani N, et al. Canadian prostate brachytherapy in 2012. Can Urol Assoc J. 2013;7(1–2):51–8.PubMedCentralPubMed
29.
Crook J, Patil N, Ma C, McLean M, Borg J. Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2010;77(4):1079–84.CrossRefPubMed
30.
Lawton C, Hunt D, Lee W, Gomella L, Grignon D, Gillin M, et al. Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys. 2011;81(1):1–7.CrossRefPubMedCentralPubMed
31.
Lawton C, DeSilvio M, Lee W, Gomella L, Grignon D, Gillin M, et al. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). Int J Radiat Oncol Biol Phys. 2007;67(1):39–47.CrossRefPubMed
32.
Gleason DF. Histological Grading and Clinical Staging of Prostatic Carcinoma. In: Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia: Lea & Feibiger; 1977. p. 171–98.
33.
Nag S, Bice W, DeWyngaert K, Prestidge B, Stock R, Yu Y. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys. 2000;46(1):221–30.CrossRefPubMed
34.
Johnny K, Nelson N, Stone MD, Amir L, Vishruta D, Cesaretti JA, et al. I125 monotherapy using D90 implant doses of 180 Gy or greater. Int J Radiat Oncol Biol Phys. 2008;70(1):96–101.CrossRef
35.
Taira A, Merrick G, Galbreath R, Butler W, Adamovich E, Wallner K. Prognostic importance of small prostate size in men receiving definitive prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2012;84(2):396–401.CrossRefPubMed
36.
Fuks Z, Leibel SA, Wallner KE, Begg CB, Fair WR, Anderson LL, et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys. 1991;21(3):537–47.CrossRefPubMed
37.
Zelefsky M, Withmore W. Long-term result of retropubic permanent 125 iodine implantation of the prostate for clinically localized prostatic cancer. J Urol. 1997;158:23–30.CrossRefPubMed
38.
Nag S, Baird M, Blasko J. American brachytherapy society (ABS) survey of current clinical practice for permanent brachytherapy of prostate cancer. J Brachytherapy Int. 1997;13:243–51.
39.
Stone N, Potters L, Davis B, Ciezki J, Zelefsky M, Roach M, et al. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys. 2007;69(5):1472–7.CrossRefPubMed
40.
Otón C, Otón L. Brachytherapy doses for prostate cancer customized to risk factors: is it more important “how much” or “where”? In regard to Stone et al. Int J Radiat Oncol Biol Phys. 2008;71(3):962–3.CrossRefPubMed
41.
ICRU Report 50. Prescribing, Recording and reporting photon beam therapy. In: ICRU report 50. Bethesda, USA: ICRU; 1993. p. 5–27.
Metadata
Title
Comparing CTVs for permanent prostate brachytherapy
Authors
C. A. Oton
L. Blanco
L. F. Oton
S. Moral
Publication date
01-05-2015
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 5/2015
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1245-z

Other articles of this Issue 5/2015

Clinical and Translational Oncology 5/2015 Go to the issue

Research Article

Interleukin-8 promotes human ovarian cancer cell migration by epithelial–mesenchymal transition induction in vitro

Research Article

High serum microRNA-335 level predicts aggressive tumor progression and unfavorable prognosis in pediatric acute myeloid leukemia

Research Article

Differential expression profiling of microRNAs in para-carcinoma, carcinoma and relapse human pancreatic cancer

Research Article

Tissue fatty acid composition and secretory phospholipase-A2 activity in oral squamous cell carcinoma

Research Article

The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials

Educational Series – Blue Series

Immunotherapy in prostate cancer: review of the current evidence
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits